COMMUNIQUÉS West-GlobeNewswire

Verano Enters Cannabis Beverage Category with Debut of Easy Landings, Company’s First National Beverage Brand Featuring Four Delicious Flavors and All-Natural Ingredients
20/08/2026
Leveraging consumer trends favoring alternative and macrodose cannabis products, THC drinks and alcohol-free options, Easy Landings 100 mg single serve beverages feature four delicious flavors with all natural, vegan [...]
Why Work With Transcom: Disability Inclusion Recognized for a Second Year
20/08/2026
Transcom is recognized for the second consecutive year as a World’s Top Disability Inclusive Business on the Disability Index®, a leading global benchmark for workplace disability inclusion. In 2026, Transcom operations [...]
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
20/08/2026
Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exclusive option to [...]
NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution
20/08/2026
Executing NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholders Appointed Srishti Gupta, MD, MPP, as Chief Executive Officer, to [...]
Tilray Strengthens Global Medical Cannabis Leadership with Major Production Increase to Meet International Demand
20/08/2026
Expanded cultivation in Quebec and Portugal strengthens Tilray’s global cannabis platform, increasing total annual production capacity to approximately 275 metric tonnes to support accelerating international medical [...]
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
20/08/2026
Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest NASHVILLE, Tenn., Aug. 20, [...]
Grey Matters Announces CAD $800K of Private Placement Equity Financing and Convertible Debentures
20/08/2026
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “ Company” or “ Grey Matters ”) (CSE [...]
George Medicines announces GMRx2 presentations at the European Society of Cardiology Congress 2026
20/08/2026
London, UK, Boston, MA, 20 August 2026 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, today announced that data on GMRx2, its single [...]
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
20/08/2026
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe and well tolerated [...]
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
20/08/2026
Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated clinical proof-of- [...]
Herantis Pharma releases 1H 2026 report today
20/08/2026
Espoo, Finland, August 20, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, releases today the Company’s 1H 2026 [...]
Flyte Surpasses 10,000 Consumer Accounts as WebApp Growth Accelerates
20/08/2026
New Account Creation Increased 170% During the First 17 Days of August Compared to the Same Period in July Flyte Has Added More Accounts Since July 1 Than During the Entire First Half of 2026 Growing First-Party [...]
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
20/08/2026
Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual Investor Event to [...]
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
20/08/2026
Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial [...]
InflaRx Announces Participation in September Investor Conferences
20/08/2026
Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate [...]
Evaxion announces business update and second quarter 2026 financial results
20/08/2026
COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and [...]
VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX C001 in urgent surgery
20/08/2026
VarmX enrols first participant in global Phase 3 EquilibriX‑S trial evaluating VMX‑C001 in urgent surgery First participant enrolled:  EquilibriX‑S (NCT07288489), a landmark registrational Phase 3 study of VMX-C001 vs [...]
Adagene to Participate in Three Upcoming Investor Conferences
20/08/2026
SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based [...]
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
20/08/2026
Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progression Actively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03 [...]

Pages